申请人:Tarapeutics Science Inc.
公开号:EP3896059A1
公开(公告)日:2021-10-20
Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.
本发明公开了一种激酶抑制剂和包含该激酶抑制剂的药物组合物。激酶抑制剂包括式(I)所代表的化合物或其药学上可接受的盐、溶液剂、酯、酸、代谢物或原药。上述化合物和组合物可以抑制野生型 KIT 和/或突变型 KIT 酪氨酸激酶活性,治疗、预防或缓解与野生型 KIT 和/或突变型 KIT 激酶活性相关的疾病、失调或病症。